Juan-Gonzalo Correa
Overview
Explore the profile of Juan-Gonzalo Correa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
161
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Visentin A, Chatzikonstantinou T, Scarfo L, Kapetanakis A, Demosthenous C, Karakatsoulis G, et al.
Am J Hematol
. 2023 Sep;
98(12):1856-1868.
PMID: 37772428
In this retrospective international multicenter study, we describe the clinical characteristics and outcomes of patients with chronic lymphocytic leukemia (CLL) and related disorders (small lymphocytic lymphoma and high-count monoclonal B...
2.
Chatzikonstantinou T, Kapetanakis A, Scarfo L, Karakatsoulis G, Allsup D, Cabrero A, et al.
Leukemia
. 2021 Nov;
35(12):3444-3454.
PMID: 34725454
Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome...
3.
Hernandez-Boluda J, Pereira A, Alvarez-Larran A, Martin A, Benzaquen A, Aguirre L, et al.
Biol Blood Marrow Transplant
. 2020 Jul;
26(12):2237-2244.
PMID: 32717433
Accurate prognostic tools are crucial to assess the risk/benefit ratio of allogeneic hematopoietic cell transplantation (allo-HCT) in patients with myelofibrosis (MF). We aimed to evaluate the performance of the Myelofibrosis...
4.
Pastor-Galan I, Hernandez-Boluda J, Correa J, Alvarez-Larran A, Ferrer-Marin F, Raya J, et al.
Med Clin (Barc)
. 2020 Jan;
155(4):152-158.
PMID: 31980217
Material And Methods: A total of 1,000 patients from the Spanish Registry of Myelofibrosis diagnosed with primary (n=641) or secondary (n=359) myelofibrosis were analysed. Results: Median age was 68 years....
5.
Alvarez-Larran A, Lopez-Guerra M, Rozman M, Correa J, Hernandez-Boluda J, Tormo M, et al.
Ann Hematol
. 2019 Aug;
98(10):2319-2328.
PMID: 31396671
Triple-negative primary myelofibrosis (TN-PMF) and other myeloid neoplasms with associated bone marrow fibrosis such as the myelodysplastic syndromes (MDS-F) or the myelodysplastic/myeloproliferative neoplasms (MDS/MPN-F) are rare entities, often difficult to...
6.
Hernandez-Boluda J, Pereira A, Correa J, Alvarez-Larran A, Ferrer-Marin F, Raya J, et al.
Ann Hematol
. 2018 Feb;
97(5):813-820.
PMID: 29396714
Prognostic models are widely used in clinical practice for transplant decision-making in myelofibrosis (MF). We have compared the performance of the International Prognostic Scoring System (IPSS), dynamic IPSS (DIPSS), and...
7.
Hernandez-Boluda J, Correa J, Alvarez-Larran A, Ferrer-Marin F, Raya J, Martinez-Lopez J, et al.
Br J Haematol
. 2017 Apr;
181(3):397-400.
PMID: 28419426
No abstract available.
8.
Hernandez-Boluda J, Correa J, Garcia-Delgado R, Martinez-Lopez J, Alvarez-Larran A, Fox M, et al.
Eur J Haematol
. 2016 Dec;
98(4):407-414.
PMID: 28009442
Objective: Erythropoiesis-stimulating agents (ESAs) are commonly used to treat the anemia of myelofibrosis (MF), but information on the predictors of response is limited. Methods: Results of ESA therapy were analyzed...
9.
Cervantes F, Correa J, Perez I, Garcia-Gutierrez V, Redondo S, Colomer D, et al.
Ann Hematol
. 2016 Oct;
96(1):81-85.
PMID: 27717993
To determine whether a lower imatinib dose could minimize toxicity while maintaining the molecular response (MR), imatinib dose was reduced to 300 mg daily in 43 patients with chronic myeloid...
10.
Cervantes F, Correa J, Hernandez-Boluda J
Expert Rev Hematol
. 2016 Feb;
9(5):489-96.
PMID: 26891375
Anemia and thrombocytopenia are frequent clinical manifestations of myelofibrosis as well as important prognostic factors of the disease. Concerning the treatment of anemia, the first step should be the correction...